am-630 has been researched along with Body-Weight* in 3 studies
3 other study(ies) available for am-630 and Body-Weight
Article | Year |
---|---|
CB2 cannabinoid receptor is involved in the anti-inflammatory effects of leptin in a model of traumatic brain injury.
The rates for traumatic brain injury (TBI) have risen in the last decade. Studies in animal models and clinical trials have not yet resulted in an effective treatment for TBI. Leptin, a 16kDa peptidic hormone is mainly known as a regulator of energy balance and has been shown to exert neuroprotective effects in different models of brain pathology. In this study, we have assessed whether leptin exerts protective actions in a TBI mouse model. In addition, the possible implication of CB2 cannabinoid receptor in leptin actions has been explored, since it is known that the endocannabinoid system interacts with leptin and actively participates in brain recovery after lesions.. Swiss (CD1) male mice were subjected to weigh-drop model for TBI. Prior to the lesion, mice were injected with an antagonist of CB2 receptor (AM630) or the vehicle and immediately after TBI, they received leptin or vehicle treatment. Data were analyzed using a two-way ANOVA or the non-parametric test Kruskal-Wallis when appropriate. For correlation analyses, Spearman's rho test, followed by linear regression test, was used.. TBI induced a neurological deficit, which was improved by leptin treatment. Leptin recovered several parameters affected by TBI, including the expression of cannabinoid receptors, axonal injury marker and neuroinflammatory components. The effects of leptin were prevented or reduced when it was administered in combination with the CB2 receptor antagonist, AM630.. Since some of the beneficial effects of leptin were not evident in the presence of AM630, our results suggest that CB2 receptor might be involved in the full expression of the neuroprotective effects of the hormone. These findings open new avenues for the study of leptin as a therapeutic treatment for TBI and enhance the importance of CB2 receptor in TBI pathophysiology and recovery. Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Axons; Behavior, Animal; Body Weight; Brain Injuries; Cannabinoid Receptor Antagonists; Cytokines; Indoles; Leptin; Male; Mice; Nervous System Diseases; Neuritis; Neuroprotective Agents; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2016 |
Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat.
Periodontitis is an infectious disease leading to inflammation and destruction of tissue surrounding and supporting the tooth. The progress of the inflammatory response depends on the host's immune system and risk factors such as stress. The aim of the present study was to investigate the role of the endocannabinoid anandamide (AEA) in experimental periodontitis with restraint stress, since the endocannabinoid system is known to modulate the hypothalamo-pituitary-adrenal axis as well as immune functions and has been found in human gingival tissues.. Experimental periodontitis was induced by ligature around first inferior molars and immobilization stress for 2 h twice daily for 7 days in a rat model.. Corticosterone plasma levels, locomotor activity, adrenal gland weight and bone loss were increased in periodontitis and stress groups, and there was also less weight gain. The inflammatory parameters such as prostaglandin E(2) (radioimmunoassay), nitric oxide (radioconversion of (14)C-arginine), tumor necrosis factor (TNF)-α (ELISA) and interleukin (IL)-1β (Western blot) measured in the gingival tissue were significantly increased in the periodontitis groups compared to the control group. Local injection of AEA (10(-8)M, 30 µl) decreased corticosterone plasma levels and the content of the cytokines TNF-α and IL-1β in gingival tissue in periodontitis-stress groups. These AEA-induced inhibitions were mediated by CB(1) and CB(2) cannabinoid receptors since the injection of both antagonists together, AM251 (10(-6)M) and AM630 (10(-6)M) in 30 µl, prevented these effects.. The endocannabinoid AEA diminishes the inflammatory response in periodontitis even during a stressful situation. Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Body Weight; Cannabinoid Receptor Agonists; Corticosterone; Disease Models, Animal; Endocannabinoids; Enzyme-Linked Immunosorbent Assay; Exploratory Behavior; Indoles; Interleukin-1beta; Male; Nitric Oxide Synthase; Periodontitis; Piperidines; Polyunsaturated Alkamides; Prostaglandins E; Pyrazoles; Rats; Rats, Wistar; Statistics, Nonparametric; Stress, Psychological; Tumor Necrosis Factor-alpha | 2012 |
Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors.
Cannabidiol (CBD) is a major non-psychotropic constituent of Cannabis sativa, with well recognized therapeutic potential. Considering the importance of the endogenous cannabinoid system to the regulation of food intake and energy balance we studied the effects of repeated CBD administration on body weight gains in rats. Male Wistar rats (260 ± 20 g at start of study) received intraperitoneal injections of CBD at doses of 2.5 and 5mg/kg/day for 14 consecutive days and body weight gains were monitored. Both doses of CBD produced significant decrease in body weight gain, with the effect produced by 5mg/kg being more pronounced. The CB2 receptor selective antagonist, AM630, blocked the decrease in body weight gain. AM630 alone did not affect body weight gain. The results suggest that CBD has the ability to alter body weight gain, possibly via the CB2 receptor. CB2 receptors may play a role in the regulation of body weight and the effects of CB2 specific ligands should be further investigated in studies of body weight regulation. Topics: Animals; Body Weight; Cannabidiol; Dose-Response Relationship, Drug; Indoles; Male; Rats; Rats, Wistar; Receptor, Cannabinoid, CB2; Time Factors | 2011 |